AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

What is the purpose of this trial?

Objectives

  • Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
  • Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Participation Guidelines

Ages: 45 years and older

Gender: Both


National Institute of Neurological Disorders and Stroke

Start Date: 11/27/2018

End Date: 01/18/2022

Last Updated: 12/17/2018

Study HIC#: 2000024124

Get Involved

For more information about this study, contact:
Sara Jasak
+1 203-737-7629
sara.jasak@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Reshma Narula

Principal Investigator

Sub-Investigators